1. Review existing understanding of the genomics and immune environment in DLBCL
2. Discuss a computational approach in examining the immune environment in DLBCL
3. Discuss ongoing work using transcriptomics to identify markers of early relapse in DLBCL after CAR-T cell therapy.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation